Scientists Present Positive Progress in the Development of a New Class of Broad-spectrum Organogold Antibiotics

Cambridge, UK, and Stevenage, UK, 12th September 2017 / Sciad Newswire / Domainex and Auspherix have announced new data from their collaboration to develop novel candidate drugs to tackle the growing threat of resistance to antibiotics.

The exciting data, disclosed yesterday in both a poster and an oral presentation by Dr Jonathan Powell from Domainex at the 19^th RSC / SCI Medicinal Chemistry Symposium in Cambridge, UK, describe the discovery of three distinct chemical series, all with broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria. Importantly the Auspherix compounds are active against the so-called ESKAPE pathogens¹ which are responsible for the majority of hospital infections.

More information can be found at at Domainex and Auspherix